🎉 M&A multiples are live!
Check it out!

Editas Medicine Valuation Multiples

Discover revenue and EBITDA valuation multiples for Editas Medicine and similar public comparables like Pharming, Julphar, and Vivoryon Therapeutics.

Editas Medicine Overview

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.


Founded

2013

HQ

United States of America
Employees

246

Financials

LTM Revenue $25.8M

LTM EBITDA -$211M

EV

-$125M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Editas Medicine Financials

Editas Medicine has a last 12-month revenue of $25.8M and a last 12-month EBITDA of -$211M.

In the most recent fiscal year, Editas Medicine achieved revenue of $32.3M and an EBITDA of -$233M.

Editas Medicine expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Editas Medicine valuation multiples based on analyst estimates

Editas Medicine P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $78.1M $32.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$163M -$233M XXX XXX XXX
EBITDA Margin -209% -721% XXX XXX XXX
Net Profit -$220M -$153M XXX XXX XXX
Net Margin -282% -474% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Editas Medicine Stock Performance

As of April 15, 2025, Editas Medicine's stock price is $1.

Editas Medicine has current market cap of $110M, and EV of -$125M.

See Editas Medicine trading valuation data

Editas Medicine Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$125M $110M XXX XXX XXX XXX $-2.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Editas Medicine Valuation Multiples

As of April 15, 2025, Editas Medicine has market cap of $110M and EV of -$125M.

Editas Medicine's trades at -4.9x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Editas Medicine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Editas Medicine and 10K+ public comps

Editas Medicine Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$125M XXX XXX XXX
EV/Revenue -3.9x XXX XXX XXX
EV/EBITDA 0.5x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Editas Medicine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Editas Medicine Valuation Multiples

Editas Medicine's NTM/LTM revenue growth is -66%

Editas Medicine's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Editas Medicine's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Editas Medicine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Editas Medicine and other 10K+ public comps

Editas Medicine Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -59% XXX XXX XXX XXX
EBITDA Margin -721% XXX XXX XXX XXX
EBITDA Growth 43% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -788% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 223% XXX XXX XXX XXX
R&D Expenses to Revenue 617% XXX XXX XXX XXX
Opex to Revenue 839% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Editas Medicine Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Editas Medicine M&A and Investment Activity

Editas Medicine acquired  XXX companies to date.

Last acquisition by Editas Medicine was  XXXXXXXX, XXXXX XXXXX XXXXXX . Editas Medicine acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Editas Medicine

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Editas Medicine

When was Editas Medicine founded? Editas Medicine was founded in 2013.
Where is Editas Medicine headquartered? Editas Medicine is headquartered in United States of America.
How many employees does Editas Medicine have? As of today, Editas Medicine has 246 employees.
Who is the CEO of Editas Medicine? Editas Medicine's CEO is Dr. Gilmore O’Neill, M.B..
Is Editas Medicine publicy listed? Yes, Editas Medicine is a public company listed on NAS.
What is the stock symbol of Editas Medicine? Editas Medicine trades under EDIT ticker.
When did Editas Medicine go public? Editas Medicine went public in 2016.
Who are competitors of Editas Medicine? Similar companies to Editas Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Editas Medicine? Editas Medicine's current market cap is $110M
What is the current revenue of Editas Medicine? Editas Medicine's last 12-month revenue is $25.8M.
What is the current EBITDA of Editas Medicine? Editas Medicine's last 12-month EBITDA is -$211M.
What is the current EV/Revenue multiple of Editas Medicine? Current revenue multiple of Editas Medicine is -4.9x.
What is the current EV/EBITDA multiple of Editas Medicine? Current EBITDA multiple of Editas Medicine is 0.6x.
What is the current revenue growth of Editas Medicine? Editas Medicine revenue growth between 2023 and 2024 was -59%.
Is Editas Medicine profitable? Yes, Editas Medicine is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.